Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supply Chain Confidentiality Doesn’t Stand 'Sunshine Test', Califf Says

FDA Commissioner Makes Comments On Drug Shortages At ISPE Annual Meeting

Executive Summary

US FDA commissioner takes aim at supplier confidentiality in remarks at ISPE annual meeting. But while greater transparency would help avert individual shortages, better economics for generic drugs are needed to solve the problem, he said.

You may also be interested in...



Pfizer Rallies To Fix Tornado Damage At Key Injectables Plant

In the aftermath of tornado damage to Pfizer’s US Rocky Mount sterile injectables plant, the company has set out relief efforts while acknowledging the “critical role” the facility plays for the US healthcare system.

How Will Pfizer Plant’s Tornado Damage Impact Congress’s Drug Shortages Debate?

The stakes on Capitol Hill rose another notch as tornado hit supplies of sterile injectable drugs at North Carolina plant. Workers escaped serious injury by gathering in designated shelters; patients may need effective legislation to escape serious injury from drug shortages.

FDA – And Rx Supply Chain Resiliency – Strikeout In Senate’s Draft Pandemic Prep Bill

US FDA’s attempt to address drug shortage and supply chain weaknesses in the upcoming reauthorization of pandemic preparedness legislation looks unlikely as both chambers of Congress have now thrown wrenches in the plan.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel